Transforming life for patients with Parkinson’s disease
Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.
Two clinical phase II candidates
Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >
Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >
Proprietary technology platform
The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >
Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease.
Board member leaves IRLAB for another assignmentDecember 31, 2021 Regulatory
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.Read More >
Earnings call Q3November 10, 2021
Telco in connection with publication of quarterly report for the thrid quarter 2021 The presentation is available here (held in Swedish): https://tv.streamfabriken.com/irlab-q3-2021 To download the presentation as a pdf (in English), click here: IRLAB Q3 2021 presentation For more information Åsa Hillsten, Head of IR & Corporate Communications Telephone: +46 700 81 81 17 E-mail: […]Read More >